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Medicine, Asklepios Clinics St. Georg, Hamburg, Germany(1) Reversible and non-cell-type speciﬁc attachment to cell-
associated heparan sulfate proteoglycans.
(2) Speciﬁc and probably irreversible binding to an unknown
hepatocyte-speciﬁc preS1-receptor. This step presumably
requires activation of the virus resulting in exposure of
the myristoylated N-terminus of the L-protein [1].
(3) Two different entry pathways have been proposed: (3A)
endocytosis followed by release of nucleocapsids from
endocytic vesicles; (3B) fusion of the viral envelope at
the plasma membrane.
(4) Cytoplasmic release of the viral nucleocapsid containing
the relaxed circular partially double stranded DNA (rcDNA)
with its covalently linked polymerase.
(5) Transport of the nucleocapsid along microtubules. Accu-
mulation of the capsids at the nuclear envelope facilitates
interactions with adaptor proteins of the nuclear pore
complex.
(6) Possible trapping of the nucleocapsid in the nuclear basket
and release of rcDNA into the nucleoplasm. The mecha-
nisms determining the breakdown of the capsid and the
release of the viral DNA genome are unsolved [2].
(7) ‘‘Repair” of the incoming rcDNA: Completion of the plus
strand of the rcDNA by the viral polymerase. Removal of
the polymerase from the 50-end of the minus strand
DNA. Removal of a short RNA-primer used for the DNA-
plus strand synthesis. Both processes are mediated by cel-
lular enzymes [3].
(8) cccDNA formation by covalent ligation of both DNA
strands (reviewed in [3]). The cccDNA molecule is orga-
nized as a chromatin-like structure displaying the typical
beads-on-a string arrangement consisting of both histone
and non-histone proteins (minichromosome) [4]. The lack
of cccDNA in artiﬁcial host cells (e.g. hepatocytes of HBV
transgenic mice) suggests that host speciﬁc factors may
regulate cccDNA formation.
(9) Transcription. The cccDNA utilizes the cellular transcrip-
tional machinery to produce all viral RNAs necessary for
protein production and viral replication. Both host tran-
scription factors, such as CCAAT/enhancer-binding protein
(C/EBP) and hepatocyte nuclear factors (HNF) and viral
proteins (core, the regulatory X-protein) regulate this
process [4] and may modulate viral gene expression byJournal of Hepatology 20
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overlapping open reading frames (ORFs): (I) the precore/
core gene, coding for the nucleocapsid protein and for
the non-structural, secreted, precore protein, the HBeAg;
(II) the polymerase gene coding for the reverse transcrip-
tase, RNase H and terminal protein domains; (III) the
L-,M-, and S-gene, coding for the three envelope proteins,
which are synthesized in frame from different promoters;
and (IV) the X gene, coding for the small regulatory X-pro-
tein. A correlation between viremia levels and the acetyla-
tion status of cccDNA-bound histones has been reported
[5], indicating that epigenetic mechanisms can regulate
the transcriptional activity of the cccDNA.
(10) All 4 major mRNAs utilize a single common polyadenyla-
tion signal. Processing of viral RNAs, nuclear export as
well as stabilization of the viral RNAs appears to be exclu-
sively mediated by host factors (i.e. La RNA binding
protein).
(11) Translation of the pregenomic RNA (pgRNA) to the core
protein and the viral polymerase. The regulatory X-protein
and the three envelope proteins are translated from the
subgenomic RNAs.
(12) Complex formation of the pgRNA (via its epsilon stem-
loop structure) with the core protein and the polymerase
and self-assembly of an RNA-containing nucleocapsid.
(13) Reverse transcription of the pgRNA followed by plus-
strand DNA-synthesis within the nucleocapsid. Matura-
tion of the RNA-containing nucleocapsids to DNA-contain-
ing nucleocapsids within the cytoplasm.
(14) DNA-containing nucleocapsids can be either re-imported
into the nucleus to form additional cccDNA molecules
(14A) or can be enveloped for secretion (14B). The enve-
lope proteins are co-translationally inserted into the ER
membrane, where they bud into the ER lumen, and are
secreted by the cell, either as 22 nm subviral envelope par-
ticles (SVPs) or as 42 nm infectious virions (Dane particles)
if they have enveloped the DNA-containing nucleocapsids
before budding. During synthesis of the L-protein, the
preS-domains remain cytoplasmically exposed and
become myristoylated. At some step after preS-mediated
nucleocapsid envelopment translocation across the mem-
brane occurs.
(15) Experiments performed using duck hepatitis B revealed
that the majority of cccDNA molecules in infected hepato-
cytes comes from newly synthesized nucleocapsids. 1–50
cccDNA molecules appear to accumulate per cell, though10 vol. 52 j 282–284
JOURNAL OF HEPATOLOGY
Journal of Hepatology 2010 vol. 52 j 282–284 283
Hepatology Snapshot
differences in cccDNA dynamics and efﬁciency of cccDNA
accumulation may exist between HBV and the other hep-
adnaviruses. Both viral and host factors controlling cccDNA
formation and pool size are yet poorly deﬁned. A negative-
feedback mechanism suppressing cccDNA ampliﬁcation
might involve the L-protein. As HBV polymerase inhibitors
do not directly affect the cccDNA, a decrease in cccDNA
levels is supposed to derive from the lack of sufﬁcient recy-
cling of viral nucleocapsids to the nucleus, due to inhibi-
tion of viral DNA-synthesis in the cytoplasm, and less
incoming viruses from the blood [6].
(16) Compared to virions spherical and ﬁlamentous SVPs are
secreted in a 103–106-fold excess into the blood of infected
individuals. SVPs lack a nucleocapsid and are therefore
non-infectious.
Therapeutic agents interfering with HBV life-cycle: (I) Acyl-
ated preS1-peptides have been shown to bind the HBV-receptor
and block viral entry in vivo [7]; (II) Dihydroarylpyrimidines
interfere with nucleocapsid assembly and induce core protein
degradation [8]. (III) Polymerase inhibitors suppress reverse tran-
scription and synthesis of the DNA-plus strand. The preS1-
derived lipopeptides and the dihydroarylpyrimidines are pres-
ently in preclinical development. Nucleos(t)ide analogues (Lami-
vudine, Adefovir, Entecavir, Telbivudine, Tenofovir) and
interferon (IFN) a / PEG-IFN a are the only currently approved284 Journal of Hepatology 201therapeutic treatments. IFN a inhibits HBV both through immune
modulatory effects and directly by reducing steady-state levels of
HBV transcripts.References
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